Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 03 March 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in March.

        TD Cowen 46^th Annual Healthcare Conference
        Presentation: Tuesday, March 3, 2026, at 2:30 p.m. EST

        Leerink 2026 Global Healthcare Conference
        Fireside Chat: Monday, March 9, 2026, at 3:40 p.m. EST

        Barclays 28^th Annual Global Healthcare Conference
        1x1s and small group meetings: Tuesday, March 10, 2026

        UBS Biotech Summit Miami, Catalyst for Change
        1x1s and small group meetings: Tuesday, March 10, 2026

        Jefferies 2026 Biotech on the Beach Summit
        1x1s and small group meetings: Wednesday, March 11, 2026

Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentations will be made available for a limited time.

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs​ in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Contact Information

Immunocore

Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: [email protected]
Follow on LinkedIn: @Immunocore

Investor Relations

Morgan Morse
T: +1 (215) 384-4781
E: [email protected]

You May Also Be Interested In

• She Made it – the Youngest South African Woman to Swim the Channel
• Small Business, Big Trust: How Local Locksmiths Compete With National Call Centers
• Why Visual Asset Repurposing Is Becoming a Competitive Advantage